Director Lawrence D. Kingsley of IDEXX Laboratories executed a stock transaction on Sept. 4, 2026, selling 2,203 shares for a combined value of $1.2 million. The transaction was structured as an exercise-and-sell, wherein Kingsley converted options into common stock at $114.17 per share before immediately selling them at a weighted average price of $532.08 per share.
Following the transaction, Kingsley maintained a direct ownership position of 9,568 shares of IDEXX common stock, representing approximately 0.0121% of the company. Based on market pricing as of Sept. 4, 2026, this remaining stake held a market value of $5.12 million. The director’s direct shareholding remained effectively unchanged from pre-transaction levels, as the shares sold were newly issued from the option exercise.
IDEXX Laboratories, headquartered in Westbrook, operates as a global animal diagnostics and software solutions provider with approximately 11,000 employees. The company generated trailing-twelve-month revenue of $4.6 billion and net income of $1.1 billion. With a market capitalization of $41.0 billion, IDEXX serves veterinary clinics, agricultural producers in livestock and dairy sectors, and water quality testing laboratories through its diagnostic instruments, consumables, software platforms, and related services.
The company’s business model emphasizes recurring revenue streams from its installed customer base through diagnostic consumables and software subscriptions. IDEXX’s primary market focus centers on companion animal diagnostics, though it maintains diversified revenue contributions across livestock, poultry, dairy, and water quality segments. As of the market close on Sept. 9, 2026, IDEXX shares closed at $515.15.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI